FDA Unveils Groundbreaking Guidance for AI-Enabled Medical Devices

The FDA is set to publish new draft guidance on January 7 aimed at developers of AI-enabled medical devices, offering recommendations for marketing submissions and regulatory oversight throughout the product life cycle. This guidance represents a comprehensive framework for the management of these devices, emphasizing the importance of early and continuous engagement between developers and the agency. It builds on previous guidance regarding change control for AI and machine learning components, which helps facilitate device updates without requiring new marketing submissions. The FDA's initiative also focuses on ensuring transparency and addressing bias in AI systems, providing developers with essential resources for navigating the complexities of integrating AI in healthcare.

Opens on Healthcare IT News